XML 38 R26.htm IDEA: XBRL DOCUMENT v3.26.1
Segment Information
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Segment Information Segment Information
The Company operates as a single operating segment that is engaged in discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. A global research and development organization and a supply chain organization discover, develop, manufacture, and supply our products. A global commercial organization markets, distributes, and sells the products. The business is also supported by global corporate staff functions. The Company’s Chief Operating Decision Maker (the “CODM”) is the Chief Executive Officer, who assesses performance and allocates resources based on significant expenses and net income on a consolidated basis. The significant expenses that are regularly provided to the CODM include those amounts that are also reported on the consolidated statement of operations as well as below additional disaggregated measures. The CODM also reviews cash position (which are cash and cash equivalents, current restricted cash, and short-term investments) that are also reported on the consolidated balance sheets when making operating decisions. In accordance with ASC 280, the Company has only one reportable segment.
The following tables present disaggregated expenses that are regularly provided to the CODM:
Three Months Ended March 31,
20262025
Personnel compensation and related costs18,470 24,079 
Licensing fees22,000 19,997 
CROs/CMOs/Investigators expenses19,540 9,830 
Other costs5,581 6,823 
Total research and development expenses65,591 60,729 
Three Months Ended March 31,
20262025
Clinical programs31,090 28,092 
Pre-Clinical programs11,716 3,314 
Unallocated research and development expenses22,785 29,323 
Total research and development expenses65,591 60,729 

Three Months Ended March 31,
20262025
Personnel compensation and related costs41,060 40,643 
Other costs24,010 22,779 
Total selling, general, and administrative expenses65,070 63,422 
Three Months Ended March 31,
20262025
Selling and marketing expenses43,438 41,939 
General and administrative expenses21,632 21,483 
Total selling, general, and administrative expenses65,070 63,422